📄 Showing the "Simple" version — "Advanced" is not ready yet. Add it to favorites to help prioritize it. Ask for the full read

In a car, the steering, brakes, and accelerator gradually fail. At first, you can still swerve around a pothole, but each year the maneuver takes more effort. At some point, even a perfect road becomes impassable — the car no longer obeys the driver.

That's exactly how the authors describe aging: not as the accumulation of rust or wear and tear, but as the loss of "controllability" of the body. In this picture, biological age is not the number of years lived, but the minimum price you have to pay (in drugs, procedures, time) to bring the body back into a safe, working zone. The older the system, the more expensive and complex it is to "repair" it to normal.

The most surprising conclusion concerns the order of actions. Two drugs taken in different sequences can lead to opposite results, just as in a car you must first press the clutch and then shift gears, not the other way around. Mathematically, this is described by the concept of "non-commutativity" (when the result depends on the order of operations): for two interventions A and B, the effect of A followed by B is not equal to the effect of B followed by A. The authors built a model of five equations that computes the optimal sequence and dosage, and then tested it on real data on age-related changes.

The practical goal is not just to find another "anti-aging drug," but to give pharmacologists a tool to calculate which intervention, at what time, and in what combination will truly rejuvenate cells, rather than just shift lab values. The authors formulated twenty testable predictions — if they hold, the search for therapy will become not a blind trial-and-error, but a precise engineering calculation.

Original abstract

as written by the authors arXiv:2605.16781

Existing aging theories describe what changes with age but do not prescribe how to intervene. We propose a control-theoretic framework that is not merely descriptive but prescriptive: it specifies which intervention, at which dose and sequence, under which safety constraints, will restore a measured biological state to a functional region. Aging is defined as progressive loss of safe controllability; biological age is the minimum safe control cost of functional restoration. Drugs are modeled as vector fields on biological state space whose non-commutativity, quantified by Lie brackets, predicts that intervention order determines outcome. The core differentiation from prior theories is operational: the framework outputs ranked targets, optimal sequences, safety-constrained protocols, and falsifiable predictions directly usable in drug discovery, rather than mechanistic ontologies or correlative biomarkers. We present a five-dimensional ODE model with analytic Lie-bracket derivation, a modality-aware control layer, three translational case studies, an implementation architecture with power analysis, and empirical scoring of aging interventions across five biological epochs. Twenty falsifiable predictions are enumerated. The central claim is that control-value reduction predicts translational success better than Hallmark annotation or biomarker reversal alone. If validated, this provides the missing interventional layer connecting aging biology to rational gerotherapeutic discovery.